A

ABRUZZESE ELISABETTA

Last name: ABRUZZESE ELISABETTA

2020 (v1)

Publication

Metadata-only

Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data

Palandri Francesca Breccia Massimo. Tiribelli Mario

The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF patients treated with ruxolitinib, we investigated incidence and risk factors for BP and we described outcome according to disease characteristics and treatment strategy. After a median follow-up from ruxolitinib...

Uploaded on: April 14, 2023